Panacea Acquisition Corp. II
Cash in trust
$175M
$174,912,374
Trust per share
$10.14
Redemption value
IPO
Apr 2021
—
Combination deadline
—
Not disclosed
Filings on record
57
Latest Feb 14, 2024
Overview
Panacea Acquisition Corp. II is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0001828989. It completed its initial public offering in Apr 2021. The vehicle is sponsored by EcoR1 Panacea through EcoR1 Panacea Holdings II, LLC. The mandate targets healthcare. Deadline lapsed without a deal; trust returned to public shareholders.
“we expect to focus our search for a target business in the biotechnology sector, we will consider a business combination outside of our management’s areas of expertise if such business combination candidate is presented to us and we determine that such candidate offers an attractive acquisition opportunity for our company.”
Reading the filings
Arithmetic on what Panacea Acquisition Corp. II has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Trust versus the $10 unit
The trust holds $10.14 per public share, 1.4% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.
Sponsor record
EcoR1 Panacea has launched 2 vehicles. Of the 2 that have resolved, 1 closed a combination and 1 liquidated, a 50% completion rate. A sponsor's record is not a forecast, but it does tell you whether the team has taken a deal across the line before.
Underwriting
Cowen led the offering. It has been named on 29 SPAC IPOs, book-running 23 of them, and 71.4% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.
57 filings in all. 1 in the last three months, against a busiest month of 23.
News on Panacea Acquisition Corp. II
Last 90 daysNothing in the last 90 days that names this vehicle. We attribute a story only when the release carries the ticker or the registered name, so an empty section means no press release or wire story matched — not that nothing was published. The filings below are the primary record either way.
SEC filing history
Free tier: filings older than 24 hours- SC 13G/A
683 CAPITAL MANAGEMENT, LLC
Accession 0001085146-24-001414
- 4
Statement of changes in beneficial ownership
Accession 0001209191-23-026595
- 15-12G
Deregistration of securities
Accession 0001213900-23-033685
- 25-NSE
Notification of delisting
Accession 0001354457-23-000285
- 8-K
Other events
Item 8.01 · Accession 0001213900-23-028589
- 10-K
Annual report
Accession 0001213900-23-024649
- SC 13G/A
SC 13G/A
Accession 0001104659-23-020720
- SC 13G/A
SC 13G/A
Accession 0001193125-23-037222
- SC 13G
Beneficial ownership report (passive)
Accession 0001315863-23-000261
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001040188-23-000038
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0000902664-23-000623
- 10-Q
Quarterly report
Accession 0001213900-22-071902
- 10-Q
Quarterly report
Accession 0001213900-22-048041
- 10-Q
Quarterly report
Accession 0001213900-22-027075
- 10-K
Annual report
Accession 0001213900-22-016844
- SC 13G
Beneficial ownership report (passive)
Accession 0001213900-22-007564
- SC 13G/A
SC 13G/A
Accession 0001193125-22-041212
- SC 13G
Beneficial ownership report (passive)
Accession 0001193125-22-041150
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001104659-22-021116
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001013594-22-000179
- 10-Q/A
AMENDMENT NO. 1 TO FORM 10-Q
Accession 0001213900-22-005707
- 8-K
Current report
Item 4.02 · Accession 0001213900-22-005702
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0000902664-22-001000
- SC 13G
Beneficial ownership report (passive)
Accession 0001040188-22-000053
- 10-Q
Quarterly report
Accession 0001213900-21-058684
- SC 13G
Beneficial ownership report (passive)
Accession 0000902664-21-004039
- 10-Q
Quarterly report
Accession 0001213900-21-042562
- 8-K
Notice of delisting or failure to satisfy a listing rule
Item 3.01 · Accession 0001213900-21-032371
- 10-Q
Quarterly report
Accession 0001213900-21-032186
- NT 10-Q
Late quarterly report notification
Accession 0001213900-21-028793
Pro
Track Panacea Acquisition Corp. II without the delay
Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.
- Filings live, no 24-hour delay
- One click through to the source document
- Deadline calendar out to 12 months
- CSV export, API and MCP access
Cancel any time. Billed monthly in USD.
Panacea Acquisition Corp. II: questions answered
What is Panacea Acquisition Corp. II?
Panacea Acquisition Corp. II is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0001828989. It completed its initial public offering in Apr 2021. The vehicle is sponsored by EcoR1 Panacea through EcoR1 Panacea Holdings II, LLC. The mandate targets healthcare. Deadline lapsed without a deal; trust returned to public shareholders.
How much does Panacea Acquisition Corp. II hold in trust?
Approximately $174,912,374, or about $10.14 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must Panacea Acquisition Corp. II complete a merger?
No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.
What happens if Panacea Acquisition Corp. II does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in Panacea Acquisition Corp. II, and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.14 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
Is the trust value the same as the share price for Panacea Acquisition Corp. II?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
Who sponsors Panacea Acquisition Corp. II, and what is their track record?
EcoR1 Panacea Holdings II, LLC is the sponsor entity, part of the EcoR1 Panacea franchise. That franchise has launched 2 vehicles in total, of which 1 closed a combination and 1 liquidated, a 50% completion rate on resolved vehicles. Named principals: Oleg Nodelman.
Which banks underwrote the Panacea Acquisition Corp. II IPO?
Cowen. Cowen was credited as book-running manager on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is Panacea Acquisition Corp. II a good investment?
That is not a question this site answers. Panacea Acquisition Corp. II is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this Panacea Acquisition Corp. II data come from?
Filings Panacea Acquisition Corp. II submitted to the SEC under CIK 0001828989: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Oct 19, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
EcoR1 Panacea: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
Cowen in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Healthcare SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All liquidated spacs
Deadline lapsed without a deal; trust returned to public shareholders.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.